Aridis Pharmaceuticals (ARDS) Releases Earnings Results, Misses Expectations By $0.12 EPS
Aridis Pharmaceuticals (NASDAQ:ARDS) released its earnings results on Tuesday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.12), Fidelity Earnings reports. The company had revenue of $1.02 million during the quarter.
Aridis Pharmaceuticals stock opened at $9.76 on Wednesday. Aridis Pharmaceuticals has a 52 week low of $7.59 and a 52 week high of $13.85. The stock has a market cap of $77.59 million and a P/E ratio of -1.39.
A number of analysts recently issued reports on ARDS shares. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Aridis Pharmaceuticals in a research report on Wednesday, April 17th. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, April 2nd. Finally, Maxim Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Aridis Pharmaceuticals in a research report on Monday, April 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $27.50.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
See Also: Why are gap-down stocks important?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.